Related Experiment Videos
A hexagonal (II) phase phospholipid neutralization assay for lupus anticoagulant identification
D A Triplett1, L K Barna, G A Unger
1Department of Research, Ball Memorial Hospital, Muncie, Indiana 47303.
Thrombosis and Haemostasis
|November 15, 1993
Summary
Lupus anticoagulants (LAs) are antibodies that can cause clotting issues. A new hexagonal (II) phase phospholipid assay effectively confirms LAs in diverse patient groups.
Area of Science:
- Hematology
- Immunology
- Clinical Chemistry
Background:
- Lupus anticoagulants (LAs) are immunoglobulins interfering with phospholipid-dependent coagulation tests.
- LAs are a common cause of unexplained activated partial thromboplastin time (APTT) in clinical labs.
- Diagnosing LAs is challenging due to reagent variability and antibody heterogeneity.
Purpose of the Study:
- To evaluate Staclot LA, a novel assay using hexagonal (II) phase phospholipids (egg phosphatidylethanolamine [EPE]) for LA confirmation.
- To assess the specificity of hexagonal (II) phase phospholipids in neutralizing LAs across various clinical settings.
Main Methods:
- Utilized Staclot LA assay with hexagonal (II) phase EPE as a confirmatory test.
- Tested plasma samples from diverse patient groups: LA-positive (autoimmune, drug-induced, post-infection), heparinized, oral anticoagulated, hemophilia A/B, and factor inhibitors.
Main Results:
- The Staclot LA assay demonstrated specificity in confirming LAs.
- Hexagonal (II) phase phospholipids effectively neutralized LAs in the tested patient populations.
- Findings confirmed previous observations on hexagonal (II) phase phospholipid neutralization.
Conclusions:
- Hexagonal (II) phase phospholipid assays, like Staclot LA, are specific confirmatory tests for lupus anticoagulants.
- This assay is effective across a mixed population of LA-positive patients.
- The study validates the utility of hexagonal (II) phase phospholipids in LA diagnostics.